甲基2-甲基-4,5-二氢-1H-吡咯-3-羧酸酯 | 35895-01-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 中文名称: 甲基2-甲基-4,5-二氢-1H-吡咯-3-羧酸酯
• 英文名称: 2-Methyl-3-methoxycarbonyl-Δ2-pyrrolin
• 英文别名: 2-methyl-4,5-dihydro-pyrrole-3-carboxylic acid methyl ester；Methyl 2-methyl-4,5-dihydro-1H-pyrrole-3-carboxylate；methyl 5-methyl-2,3-dihydro-1H-pyrrole-4-carboxylate
• CAS: 35895-01-3
• 化学式: C₇H₁₁NO₂
• 分子量: 141.17
• InChiKey: BZBZCULXKZYVAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  甲基1-乙酰基环丙烷羧酸酯 、 氨 以81%的产率得到
  参考文献：
  名称：

  CELERIER, J. P.;HADDAD, M.;JACOBY, D.;LHOMMET, G., TETRAHEDRON LETT., 28,(1987) N 52, 6597-6600

  摘要：

  DOI：

文献信息

• COMPOSITIONS COMPRISING A POLYMERIC NETWORK
  申请人：UNIVERSITEIT GENT

  公开号：US20170327625A1

  公开（公告）日：2017-11-16

  The present invention relates to a composition comprising a polymeric network having at least one unit of formula (I), (II), and/or (III); (I) (II) (III) wherein said composition is obtained by contacting at least one compound A comprising at least two functions selected from the group of function of formula X—C(═O)—CHR 1 —C(═O)—R 2 , —C(═O)—C—R 2 ; or —C(═O)—CR 1 ═CR 2 —NR 4 R 5 ; wherein at least 25% by weight of compounds A have a functionality ≦5, with % by weight relative to the total weight of compounds A; with at least one compound B comprising at least one NH 2 , or NH 3 + groups; wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , L 1 and L 2 have the same meaning as that defined in the claims. The present invention also relates to a compound comprising at least two units and at most 5 units of formula (I), (II), and/or (III); wherein R 1 , R 2 , R 3 , X, L 1 and L 2 have the same meaning as that defined in the claims. The present invention also relates to processes for preparing said composition and said compounds, to material, articles, and polymers comprising or using said compositions and compounds, and the use thereof.

  本发明涉及一种组合物，其包括至少一种具有式(I)、(II)和/或(III)的聚合网络单元；其中所述组合物是通过接触至少一种化合物A而获得的，所述化合物A包括至少两种选自以下功能组的功能：X—C(═O)—CHR1—C(═O)—R2，—C(═O)—C—R2；或—C(═O)—CR1═CR2—NR4R5；其中化合物A的至少25%的重量具有功能性≦5，以重量百分比相对于化合物A的总重量计算；以及至少一种包括至少一个NH2或NH3+基团的化合物B；其中X、R1、R2、R3、R4、R5、L1和L2的含义与权利要求书中定义的含义相同。本发明还涉及一种化合物，其包括至少两个单元和最多5个式(I)、(II)和/或(III)的单元；其中R1、R2、R3、X、L1和L2的含义与权利要求书中定义的含义相同。本发明还涉及制备所述组合物和所述化合物的方法，以及包括或使用所述组合物和化合物的材料、物品和聚合物，以及其用途。
• Compositions comprising a polymeric network
  申请人：UNIVERSITEIT GENT

  公开号：US10246548B2

  公开（公告）日：2019-04-02

  The present invention relates to a composition comprising a polymeric network having at least one unit of formula (I), (II), and/or (III); wherein the composition is obtained by contacting at least one compound A comprising at least two functions selected from the group of function of formula —X—C(═O)—CHR1-C(═O)—R2, —C(═O)—C≡C—R2; or —C(═O)—CR1═CR2—NR4R5; wherein at least 25% by weight of compounds A have a functionality ≤5, with % by weight relative to the total weight of compounds A; with at least one compound B comprising at least one —NH2, or —NH3+ groups; wherein X, R1, R2, R3, R4, R5, L1 and L2 have the same meaning as that defined in the claims. The present invention also relates to a compound comprising at least two units and at most 5 units of formula (I), (II), and/or (III), described hereinabove. The present invention also relates to processes for preparing the composition and the compounds, to material, articles, and polymers comprising or using the compositions and compounds, and the use thereof.

  本发明涉及一种组合物，该组合物由至少具有一个式（I）、（II）和/或（III）单元的聚合物网络组成； 其中该组合物是通过与至少一种化合物A接触而获得的，该化合物A包含至少两种选自式-X-C(═O)-CHR1-C(═O)-R2，-C(═O)-C≡C-R2；或-C(═O)-CR1═CR2-NR4R5的官能团；其中至少25%(重量)的化合物A的官能度≤5，以相对于化合物A总重量的%(重量)计；至少一种化合物B包含至少一个-NH2，或-NH3+基团；其中X、R1、R2、R3、R4、R5、L1和L2与权利要求书中所定义的含义相同。本发明还涉及一种包含至少两个单元和至多 5 个单元的式(I)、(II)和/或(III)化合物。本发明还涉及制备组合物和化合物的工艺，涉及包含或使用组合物和化合物的材料、物品和聚合物及其用途。
• Compounds
  申请人：MISSION THERAPEUTICS LTD

  公开号：US10392380B2

  公开（公告）日：2019-08-27

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

  本发明涉及新型化合物和制造去泛素化酶（DUB）抑制剂的方法。特别是，本发明涉及泛素 C 端水解酶 L1（UCHL1）的抑制。本发明进一步涉及 DUB 抑制剂在治疗癌症和其他适应症中的用途。本发明的化合物包括具有式(I)的化合物或其药学上可接受的盐，其中R1至R8如本文所定义。
• NOVEL COMPOUNDS
  申请人：MISSION THERAPEUTICS LTD

  公开号：US20190330202A1

  公开（公告）日：2019-10-31

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.